PRF Technologies Says PRF-110 Showed Comparable Efficacy to Zynrelef in Preclinical Study

MT Newswires Live06-25

PRF Technologies' (PRFX) PRF-110 demonstrated analgesic efficacy comparable to Zynrelef in a preclinical study evaluating post-operative pain treatment, the company said Thursday.

The study found that PRF-110 showed slower absorption and enhanced local tissue retention than Zynrelef, supporting prolonged drug exposure at the site of administration, PRF Technologies said.

The findings support the potential of PRF-110 as a long-acting, single-administration treatment for post-operative pain, the company said.

PRF Technologies said it plans to continue developing PRF-110 through additional studies.

Shares of the company were up 6.4% in Thursday premarket trading.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2646805384?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-06-25 21:18","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2646805384","market":"sh","top_or_hot":-1,"title":"PRF Technologies Says PRF-110 Showed Comparable Efficacy to Zynrelef in Preclinical Study","media":"MT Newswires Live","content":"<html><body><p> PRF Technologies' (PRFX) PRF-110 demonstrated analgesic efficacy comparable to Zynrelef in a preclinical study evaluating post-operative pain treatment, the company said Thursday.</p><p>The study found that PRF-110 showed slower absorption and enhanced local tissue retention than Zynrelef, supporting prolonged drug exposure at the site of administration, PRF Technologies said.</p><p>The findings support the potential of PRF-110 as a long-acting, single-administration treatment for post-operative pain, the company said.</p><p>PRF Technologies said it plans to continue developing PRF-110 through additional studies.</p><p>Shares of the company were up 6.4% in Thursday premarket trading.</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>PRF Technologies Says PRF-110 Showed Comparable Efficacy to Zynrelef in Preclinical Study</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nPRF Technologies Says PRF-110 Showed Comparable Efficacy to Zynrelef in Preclinical Study\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2026-06-25 21:18</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> PRF Technologies' (PRFX) PRF-110 demonstrated analgesic efficacy comparable to Zynrelef in a preclinical study evaluating post-operative pain treatment, the company said Thursday.</p><p>The study found that PRF-110 showed slower absorption and enhanced local tissue retention than Zynrelef, supporting prolonged drug exposure at the site of administration, PRF Technologies said.</p><p>The findings support the potential of PRF-110 as a long-acting, single-administration treatment for post-operative pain, the company said.</p><p>PRF Technologies said it plans to continue developing PRF-110 through additional studies.</p><p>Shares of the company were up 6.4% in Thursday premarket trading.</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4007","symbol_name":"制药","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2646805384","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2646805384","pubTimestamp":1782393501,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"PRF Technologies'  PRF-110 demonstrated analgesic efficacy comparable to Zynrelef in a preclinical study evaluating post-operative pain treatment, the company said Thursday.The study found that PRF-110 showed slower absorption and enhanced local tissue retention than Zynrelef, supporting prolonged drug exposure at the site of administration, PRF Technologies said.The findings support the potential of PRF-110 as a long-acting, single-administration treatment for post-operative pain, the company said.PRF Technologies said it plans to continue developing PRF-110 through additional studies.Shares of the company were up 6.4% in Thursday premarket trading.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4007":"制药","PRFX":"PRF Technologies Ltd.","PRF":"Invesco RAFI US 1000 ETF","BK4588":"碎股","BK4585":"ETF&股票定投概念"},"translate_title":"PRF Technologies表示PRF-110在临床前研究中显示出与Zynrelef相当的疗效","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"PRF":1.5,"PRFX":1},"content_text":"PRF Technologies' (PRFX) PRF-110 demonstrated analgesic efficacy comparable to Zynrelef in a preclinical study evaluating post-operative pain treatment, the company said Thursday.The study found that PRF-110 showed slower absorption and enhanced local tissue retention than Zynrelef, supporting prolonged drug exposure at the site of administration, PRF Technologies said.The findings support the potential of PRF-110 as a long-acting, single-administration treatment for post-operative pain, the company said.PRF Technologies said it plans to continue developing PRF-110 through additional studies.Shares of the company were up 6.4% in Thursday premarket trading.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":1,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.45.2","shortVersion":"4.45.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2646805384","isCrawlerRequest":true}